Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of STI-1558 (Ovydso) in Adult Subjects With Mild or Moderate COVID-19
NCT05716425Phase 3Completed
- Sponsor
- ACEA Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Jul 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ovydso with Placebo (2 arms). Primary endpoint: Time from the first dose to sustained recovery from 11 target symptoms of COVID-19 at Day 29. Started Feb 2023; status: completed.
02
Drugs
olgotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05716425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716425.